Targeting endocannabinoid receptors in atherosclerosis and metabolic dysfunction (B09)

• Subject Area: Cardiology, Angiology
• Term: since 2018
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 238187445

In Aim 1 of this funding period, we will further investigate the underlying molecular pathways of CB1-dependent effects in atherosclerosis and translate these findings to a clinically more relevant model by treating mice with a peripheral CB1 antagonist. A novel emerging target to counterbalance atherogenic inflammation is the non-classical cannabinoid-sensitive receptor GPR55. In Aim 2, we plan to generate GPR55 floxed mice for clarifying the cell-specific functions of this receptor in atherosclerosis. In Aim 3, we will explore the functional relevance of the newly discovered neuropeptide ligand PACAP27-GPR55 signaling axis in vitro and in vivo.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1123: Atherosclerosis: Mechanisms and Networks of Novel Therapeutic Targets
• Applicant Institution: Ludwig-Maximilians-Universität München
• Project Heads: Professor Dr. Stephan Herzig; Professorin Dr. Sabine Steffens